
Index

A

AADs. *See* Antiarrhythmic drugs (AADs)

ACE. *See* Angiotensin-converting enzyme (ACE)

Acetylene re-breathing technique, 152

Acute Decompensated Heart Failure National Registry (ADHERE), 141

ADEs. *See* Adverse drug events (ADEs)

Adipocytokines, 243

Adipokines

adiponectin

aging and longevity, 415–416

HF biomarker, 416–417

apelin, 418–419

definition, 411

leptin, 412–414

lipocalin-2, 420

metabolic effects, 411

omentin, 420–421

resistin, 418

visfatin/NAMPT, 419–420

WAT, 411

Adiponectin

aging and longevity

cross-sectional studies, 416

epidemiological studies, 415

HF biomarker, 416–417

mechanisms, 415

oligomeric forms, 414

transcript, 414–415

β -Adrenergic receptor

antagonists, 345

blockers, 343–344

stimulation, arterial and cardiac changes

Ca²⁺ overload and cell death, 330, 332

desensitization, 330

norepinephrine effects, 333

postsynaptic response, 330

Adverse drug events (ADEs), 85, 87, 88

Adverse drug reactions (ADRs)

aldosterone antagonists, 109

angiotensin-converting enzyme inhibitors, 108–109

angiotensin-receptor blockers, 108–109

beta-blockers, 109

calcium channel blockers (CCBs), 110

digoxin, 109–110

diuretics, 107–108

hydralazine, 110

nitrates, 110

AF. *See* Atrial fibrillation (AF)

Aging continuum, 20–22, 25

Aging myocardium

collagen cross-linking, 363–364

collagen turnover, 363

Aging population

heart failure therapy in, 127

monitoring in clinics, 85–86

dietary considerations, 90

evaluation of symptoms, 86–87

implantable cardiac devices, 90

investigations, 87–88

pharmacotherapy, 88–90

socioeconomic factors, 90–91

Aging subgroups, 21, 27

Aging subsets and HF therapy, 11

Aldosterone

antagonists, 41, 42, 53–54, 59, 109

heart failure, RAAS, 171–172

receptor antagonists, 174–175

Amiodarone, 70

AMP-activated protein kinase (AMPK) activators, 342, 344, 345

Anemia, 51

Angiogenesis, 125

Angiotensin-converting enzyme (ACE), 407. *See also* Renin-angiotensin system (RAS)

canine model, 264

diabetes, 264–265

inhibitors

adverse drug reactions, HF medications, 108–109

adverse events, 268

cough and angioedema side effects, 267–268

extracellular matrix, 385

heart failure therapy, 343

non-ACE and non-renin pathway, 267

optimize therapy of SHF, 52–53

RAAS, heart failure, 171, 173

RCT, 267–268

AT₂ receptor stimulation, 268

ST-segment-elevation myocardial infarction, 204

systolic heart failure, 59

- Angiotensin-converting enzyme (ACE) (*cont.*)
 VALIANT, 268
 vasodilator therapy, 208
 mouse model, 264
 AT₁ receptor blockade, 264
- Angiotensin receptor blockers (ARBs), 53, 59, 108–109, 173
- Antiarrhythmic drugs (AADs)
 class IA, 69–70
 class IC, 70
 class III, 70
 efficacy and safety, 71–72
 and elderly with AF, 69–71
- Anticoagulation. *See also* Oral anticoagulants
 atrial fibrillation, 72
 optimize therapy of SHF, 57–58
- Antihypertensive drug therapy, 39
- Antioxidants, 344
- Anti-renin therapy, heart failure, 172
- Apelin, 418–419
- Apoptosis
 aging effects, 339
 β1 integrin signaling pathway, 404–405
 cardiomyocytes, 428–429, 441
 caspase inhibitors, 344
 integrins, 405–406
 signaling pathways, 440
 sirtuins inhibit, 342
- Arginine vasopressin (AVP), 170
- Arterial and cardiac changes
 β-adrenergic receptor stimulation
 Ca²⁺ overload and cell death, 330, 332
 desensitization, 330
 norepinephrine effects, 333
 postsynaptic response, 330
 calsequestrin, 329
 cardiac aging, 321–322
 cardiovascular reserve
 autonomic modulation, 322
 evidence support, 322–323
 exhaustive upright exercise, 322
 hemodynamic profile, 323
 norepinephrine plasma levels, 323
 cellular and molecular mechanisms
 action potential prolongation, 325–329
 excitation–contraction coupling, 323
 myocardial changes, 324
 chronic stress markers
 myocyte hypertrophy and normal aging, 334
 operate on the edge, 332
 clinical practice threshold, 319–320
 increased frequency response
 L-type Ca²⁺ current and Ca²⁺, 331
 SERCA2, 330
 ventricular myocytes, old vs. young hearts, 329–330
 lifetime risk, 320
 myocyte progenitors, 332–334
 Na⁺–Ca²⁺ exchanger, 329
 physiology, 334–335
- Arterial stiffness, 123, 124, 126, 127
- Ascorbic acid biosynthesis, 458, 460
- Atherosclerosis, telomere biology, 355
- Atrial fibrillation (AF)
 AADs, 70–71
 efficacy and safety, 71–72
 aging, 66–69
 antiarrhythmic medications, 69
 anticoagulation, 72
 bleeding risk, 72–73
 catheter-based ablation therapy, 75–76
 class IA antiarrhythmic drugs, 69–70
 class IC antiarrhythmic drugs, 70
 class III antiarrhythmic drugs, 70
 dementia, 67
 demographic and comorbid conditions, 66
 epidemiology, 65
 HATCH score, 65
 heart failure, 24–25, 67–69
 oral anticoagulants, 73–75
 pathophysiology, 65, 67
 pharmacological treatment, 69
 stroke, 66–67
- Atrial natriuretic peptide (ANP), 138
- Autophagy
 aging effect
 autophagosomal structures, 340
 modulation, 341
 regulation, 340, 342
 AMPK activation, 344
 AMPK and autophagy activator metformin, 245
 mTOR inhibitor rapamycin, 245
 cardiomyocyte, 428–430
 SIRT1 regulation, 343
 resveratrol, 345
- B**
- Beers criteria, 113
- Beta-blockers (BBs), 39–41, 54–55, 59, 109
- Biological aging, 25
- Biomarkers. *See also* Cardiovascular aging, biomarkers
 and cardiovascular risk, 23
 heart failure
 BACH trial, 142
 cardiac troponins, 142
 challenges, 136–138
 diagnosis, 136–137
 GDF-15, 143
 management, 137–138
 NT-proBNP, 142
 physiological changes, 136
 role, 138, 143
 natriuretic peptides
 ANP, 138
 BNP, 138, 139
 Framingham cohort, 139
 NT-proBNP, 138, 139
 prognosis and management, 140–142
- Body mass index (BMI), 159, 312
- Brain natriuretic peptide (BNP), 138

C

- Ca²⁺ homeostasis
 - CaMKII, 394
 - myocardial abundance, 394–395
 - Na⁺–Ca²⁺ exchanger, 394
 - NADPH oxidase activity, 395
 - prolonged relaxation time, 393
 - PUFA, 395
 - RyR, 394
 - SMP30 effect, 458
- Calcium channel blockers (CCBs), 110
- Calcium dysregulation, 450
- Calcium-handling defects
 - aging-induced changes, 392
 - Ca²⁺-homeostasis
 - CaMKII, 394
 - myocardial abundance, 394–395
 - Na⁺–Ca²⁺ exchanger, 394
 - NADPH oxidase activity, 395
 - prolonged relaxation time, 393
 - PUFA, 395
 - RyR, 394
 - cardiac dysfunction
 - Ca²⁺-overload mechanisms, 397
 - interventions, 396
 - cardiomyocytes, 393
 - disablement process, 391
 - senility, 391
- Caloric restriction, 346
- Calsequestrin, 329
- Cardiac aging. *See also* Cardiovascular aging,
 - biomarkers
 - calcium dysregulation, 450
 - cardiomyocyte hypertrophy, 431–432
 - cellular and molecular changes, 427–432
 - in humans, 321–322
 - remodeling, 432
 - ROS, role of, 450–451
- Cardiac alterations
 - in aging, 95–96, 99
 - cardiomyocyte alterations (*see* Cardiomyocyte)
 - challenges, 102–103
 - macroscopic cardiac changes (*see* Macroscopic cardiac changes)
 - microscopic cardiac changes, 96
 - myocardial fibrosis, 96–98
 - treatment strategies, 101–102
 - in HTN and DHF, 99–100
- Cardiac devices, implantable, 90
- Cardiac dysfunction calcium-handling defects
 - Ca²⁺-overload mechanisms, 397
 - interventions, 396
- Cardiac fibrosis
 - aging myocardium
 - collagen cross-linking, 363–364
 - collagen turnover, 363
 - cardiac repair, 369
 - cellular effectors, 364–365
 - etiology, heart failure, 361
 - fibroblasts, 362
 - functional consequences, 364
 - impaired reparative reserve, 371
 - molecular signals
 - age-associated, pathways, 364–365
 - inflammatory cascades role, 365–367
 - myocardial remodeling, 362–363
 - postinfarction inflammatory response
 - defective scar formation, 369–370
 - senescence, 370
 - Smad2/3 pathway, 369
 - RAAS, 367
 - reactive and reparative, 362
 - reactive oxygen species, 367–368
 - senescent hearts, 370–371
 - TGF- β role, 368–369
- Cardiac phenotype, aging, 449–450
- Cardiac remodeling, 392
- Cardiac repair, 369
- Cardiac resynchronization therapy (CRT), 59
- Cardiomyocyte
 - aging, 428
 - intracellular remodeling, 431–432
 - stem cells failure, 429–431
 - alterations
 - myocyte senescence, 98–99
 - relaxation, 98
 - stiffness, 98
 - apoptosis, 343, 428–429, 441
 - autophagy, 428–430
 - calcium-handling defects, 393
 - cysteine 674 sulfonation in, 452
 - hypertrophy, 431–432
- Cardioprotective effect, 461–462
- Cardiovascular aging, biomarkers
 - biological changes, 305
 - concepts, 306
 - CVD, 305
 - functional impact, 306
 - genetic markers
 - apolipoprotein E, 309–310
 - telomeres, 310
 - hormones
 - DHEA, 311
 - estrogen, 310
 - GH secretion, 311
 - leptin, 311
 - testosterone, 310
 - inflammation, 308–309
 - oxidative stress
 - cyclophilin A, 308
 - 8-OH dG, 307
 - role, 307
 - risk factor, 312
 - senility, 305
 - systolic blood pressure, 312
 - WHR, 312

- Cardiovascular disease (CVD), 1, 20–21, 95, 96, 103
aging biomarkers, 305
aging-related, 19–20, 49–50
aging-related telomere shortening in, 18–19
clinical implications of aging-related changes, 50
deaths, 4, 5
vs. cancer deaths, 6
demographics and epidemiology, 3–5
effects of aging on, 49
prevalence, 4
prevention
biomarkers, of risk factors, 23
clustering, 22–23
risk, 16
Framingham risk score, 253
hazard ratios, 252
prediction of, 251, 252
reclassifying, 253
- Catheter-based ablation therapy, 75–76
- Caveats management, 52
- Cellular changes, 50
- Cellular senescence, 19
- CHADS₂VASc, 72
- Chemerin, 420
- Chloroquine (CQ), 444
- Chronic obstructive lung disease (COPD), 298
- Cognitive decline, 51
- Collagen
diastolic dysfunction
ECM protein levels, 185, 189
immune cell infiltration, 186, 188, 189
induction of fibrosis, 184, 185
levels of types I, III, 184, 186–188
MMPs, 185
SPARC, 190–193
stiffness, 188–190
TGF- β production, 188, 190
TIMP, 185
titin, 184
- ECM
age-related changes, 378
myocardial infarction, 381–382, 384
remodeling, 96–98
- Congestive heart failure (CHF), 166
- Coronary artery calcium
cardiovascular computed tomography, 249
cardiovascular risk
Framingham risk score, 253
hazard ratios, 252
prediction of, 251, 252
reclassification, 253
- clinical heart failure
CHD events, 255
tailor preventive therapies, 254
- clinical syndrome, 255
- ischemic cardiomyopathy, 255
- risk stratification
CHD risk factors, 250
Framingham/ATPIII, 251
treatment goals, 250
slow gait speed and frailty, 255
- Coronary artery disease (CAD)
cardiac rehabilitation benefits, 155, 156
primary prevention, 156–157
secondary prevention, 157–158
- Coronary heart disease (CHD), 120. *See also* Coronary artery disease (CAD)
- CVD. *See* Cardiovascular disease (CVD)
- Cyclophilin A, 308
- Cysteine 674 sulfonation (C674S), 452
- D**
- Damage-regulated autophagy modulator (DRAM), 443
- Dehydroepiandrosterone (DHEA), 311
- Desensitization, 330
- Device therapy, 58
- DHF. *See* Diastolic heart failure (DHF)
- Diabetes mellitus
exercise, 158–159
telomere biology, 355
- Diabetes Prevention Program (DPP), 158
- Diastolic dysfunction (DD), 9, 166
aging, 449–454
inflammatory induction vs. ECM regulation
age-dependent mechanisms, 184
collagen (*see* Collagen)
titin stiffness, 184
pathophysiological mechanisms, 183
perspective oxidative stress, 195
perspective therapeutic strategies, 194
- SPARC
Frank Starling mechanisms, 190
regulatory mechanisms, 191
- Diastolic heart failure (DHF), 3, 58
cardiac alterations in, 95–96, 99–100
cardiomyocyte alterations (*see* Cardiomyocyte)
challenges, 102–103
macroscopic cardiac changes (*see* Macroscopic cardiac changes)
microscopic cardiac changes, 96
myocardial fibrosis, 96–98
treatment strategies, 101–102
- challenge of diagnosing, 100–101
- prevention, 40
- progression from hypertension, 37
- treatment, 40–42
- Digoxin, 59, 109–110
serum digoxin and aging, 72, 109–110
- Diisopropyl phosphorofluoridate (DFP), 458
- Diuretic-induced hyponatremia, 177–178
- Diuretics, 55, 59, 107–108
- Dofetilide, 70
- DRAM. *See* Damage-regulated autophagy modulator (DRAM)
- Dronedarone, 70
- Drug interactions
nonprescription drugs, 112
principles, 111–112
- Dyskeratosis congenita, 353, 356

- Dyspnea, 86, 87
 left ventricular failure, 167
 RAAS, 167–168
 right ventricular failure, 167–168
- E**
- Echocardiography, 99, 100
 ECM. *See* Extracellular matrix (ECM)
 Ejection fraction, heart failure, 166
 Endothelial dysfunction, 124, 178–179
 Eplerenone, heart failure, 175
 Erythropoietin, 221
 Erythropoietin-stimulating agents (ESAs), safety
 epo administration, 237
 hemoglobin level, 238
 Erythropoietin therapy
 biological mechanisms, 222
 emerging
 asialoerythropoietin, 236
 epo administration, 236
 erythrocyte production
 aging, 223
 blood vessels, 223
 kidney, 222
 oxygen delivery, 222
 REPOS cells, 222–224
 ESA administration, 237–238
 hazards
 anemic CKD, 234
 thromboembolic events, 235
 hematopoietic *vs.* non-hematopoietic
 AKT/NF- κ B, 226
 beneficial effects, 228
 development of, 225
 EPOR mRNA is expressed, 223
 randomized double-blinded, 227
 stimulation of, 223, 224
 Estrogen, 310
 Excitation–contraction coupling
 key steps, 323, 325
 SR Ca²⁺, 323
 Exercise
 aerobic activity, 148
 benefits
 gastrointestinal function, 161
 immune function, 160
 risk of, falls, 160
 bicycle, 152
 catecholamines role, 154–155
 coronary artery disease
 cardiac rehabilitation benefits, 155, 156
 primary prevention, 156–157
 secondary prevention, 157–158
 diabetes mellitus, 158–159
 filling rates, 155
 and fitness, 154
 functional capacity and ageing, 149–154
 hypertension, 159
 ischemic heart disease, 147
 left ventricular size, 154
 muscle strengthening activities, 148
 obesity, 159–160
 physical activity, 148–150
 physiological response, 149
 precautions, 150
 prevalence, 160
 supine, 152
 systemic failures, 161–162
 systolic function, 154
 training, 99–103
 vigorous, 152
 Extracellular matrix (ECM), 431
 ACE inhibitors, 385
 age-related changes
 collagens, 378
 glycoproteins, 380
 growth factors, 381
 hyaluronan and proteoglycans, 380
 integrins, 381
 matricellular proteins, 380–381
 MMPs, 381
 summary, 378–379
 aging, 432
 and MI, 384
 Ang II receptor antagonists, 385
 beta-adrenergic antagonists, 385
 MI (*see* Myocardial infarction)
 post-MI medications, 384
 regulation *vs.* inflammatory induction, collagen
 production, 185
 type I, 186
 type III, 187
- F**
- Fibroblasts, 362
 Fibrosis, 9
 atrial, 68–69
 myocardial, 96–98
 Flecainide, 70
 Frailty, 86, 87, 90
 and calcium score, 255
 Framingham offspring cohort, 246–247
 Frank–Starling mechanism, 155, 166
 Free-radical theory, 125
 Friedreich’s ataxia, 221
- G**
- G α q-overexpressing mouse, 452–453
 Gene expression therapy, 435
 Glucose homeostasis, 460
 Glycoproteins, ECM
 age-related changes, 380
 myocardial infarction, 382–383
 Growth factors, ECM
 age-related changes, 381
 myocardial infarction, 383–384
 Growth hormone (GH), 311

H

- Healthy aging
 - benefits, 26
 - telomere length and, 20
- Heart failure (HF), 1–2
 - ACE inhibitors, 214
 - aging effect
 - apoptosis, 339
 - autophagy, 340–341
 - necrosis, 339–340
 - aging phenotype and, 16
 - alpha/beta blocker, 228
 - atrial fibrillation, 24–25
 - biological changes, 3
 - blood supply, 226
 - cardiovascular aging, 3, 11
 - categories, 3
 - clinical implications of aging-related changes, 50
 - clinical trials, 58–59, 228–234
 - contribution of risk factors, 117–119
 - definition, 48, 200
 - demographics and epidemiology, 3–5, 47–48
 - diastolic, 40
 - drug–drug interaction, 215
 - drug interactions
 - nonprescription drugs, 112
 - principles, 111–112
 - education role in prevention, 26–27
 - epo administration, 237–238
 - erythrocyte production
 - blood vessels, 223
 - kidney, 222
 - oxygen delivery, 222
 - REPOS cells, 222–224
 - estimation cost, 5
 - geriatric syndromes
 - falls and syncope, 113
 - fatigue and low energy, 114
 - polypharmacy, 112–113
 - healthy aging benefits, 26
 - HF/Low EF vs. HF/PEF, 6–7
 - HF/PEF, 200
 - HF/PSF, 200
 - hydralazine-nitrate combination, 211
 - hyponatremia, 55
 - hypertension, 23–24
 - implications
 - ACE inhibitors, 343
 - AMPK activators, 345
 - antioxidants, 344
 - autophagy stimulation, 344
 - β -adrenergic receptor antagonists, 345
 - β -adrenergic receptor blockers, 343–344
 - caloric restriction, 346
 - cardiomyocyte apoptosis, 343
 - caspase inhibitors and apoptosis blockers, 344
 - mTOR inhibitors, 345
 - necrosis inhibition, 344
 - sirtuin-activating compounds, 345
 - incidence and prevalence, 85
 - march to, 20–21
 - medications, adverse events from
 - aldosterone antagonists, 109
 - angiotensin-converting enzyme inhibitors, 108–109
 - angiotensin-receptor blockers, 108–109
 - beta-blockers, 109
 - calcium channel blockers (CCBs), 110
 - digoxin, 109–110
 - diuretics, 107–108
 - hydralazine, 110
 - nitrites, 110
 - metabolic syndrome, 24
 - mitochondrial fission/fusion, 441–442
 - monitoring in clinics, 85–86
 - dietary considerations, 90
 - evaluation of symptoms, 86–87
 - implantable cardiac devices, 90
 - investigations, 87–88
 - pharmacotherapy, 88–90
 - socioeconomic factors, 90–91
 - myocardial energy source, 440
 - myocardial infarction, 23–24, 440–441
 - nesiritide, 213
 - nitrites, 212–213
 - non-pharmacological therapies, 9–10
 - obesity, 24
 - pathophysiological considerations, 49
 - pharmacological therapies
 - aging-related issues with, 8
 - caveats, 9
 - physiological changes, 3
 - with preserved ejection fraction, 110–111
 - prevalence, 4–6
 - by sex and age, 118
 - prevention
 - by antihypertensive drug therapy, 39
 - strategies, 25–26
 - randomized controlled trials, 228
 - renin inhibitors, 214
 - resistin
 - association of, 245
 - C-reactive protein, 243
 - health ABC study, 245, 246
 - new-onset, 245
 - risk of, 243
 - sudden cardiac death, 244
 - sirtuins (*see* Sirtuins)
 - sodium nitroprusside, 213
 - statistics, 5–6
 - STEMI risk, 203
 - telomeres shortening and, 19
 - therapy, 427–439
 - in aging population, 127
 - aging subsets, 11
 - in elderly with HF/low EF, 8–9
 - in elderly with HF/PEF, 9
 - and implications, 7–8
 - outcomes with, 10
 - problems and caveats, 10–11
 - type 2 diabetes, 24
 - vasodilator therapy, 208

- Heart failure with preserved ejection fraction (HFPEF),
 117, 124, 126, 127
 definition, 183
 role of comorbidities
 anemia, 193
 cardiovascular risk factor, 194
 chronic lung disease, 194
 diabetes, 194
- Hemodynamic changes with age, 122–124
- HF. *See* Heart failure (HF)
- HF with low EF (HF/low EF)
 vs. HF with preserved ejection fraction (HF/PEF), 3
 therapy in elderly with, 8–9
- HF with preserved ejection fraction (HF/PEF)
 HF with low EF (HF/low EF) vs., 3
 therapy in elderly with, 9
- HTN. *See* Hypertension (HTN)
- Hyaluronan, ECM
 age-related changes, 380
 myocardial infarction, 383
- Hydralazine, 110
- Hydralazine-nitrate combination
 BiDiL, 212
 heart failure, 211
 LV systolic function, 212
- Hypertension (HTN)
 antihypertensive drug therapy, 39
 cardiac alterations in, 95–96, 99–100
 cardiomyocyte alterations (*see* Cardiomyocyte)
 challenges, 102–103
 macroscopic cardiac changes (*see* Macroscopic
 cardiac changes)
 microscopic cardiac changes, 96
 myocardial fibrosis, 96–98
 treatment strategies, 101–102
- diastolic HF, 37
 prevention, 40
 treatment, 40–42
- in elderly patients, 6–7
- exercise, 159
- and heart failure, 5–6, 23–24, 35–36
- left ventricular
 diastolic dysfunction, 37
 hypertrophy, 37–39
 remodeling, 6
- pathophysiology in older adults, 36–37
- pharmacotherapy, 102
- telomere biology, 354–355
- Hypertrophy, 431–432
 β 1 integrin, 406
 downstream signaling pathway, 407
- Hyponatremia, 176
- Hypotension, 10
- I**
- Ibutilide, 70
- Immunosenescence, 309
- Impaired metabolism, 125
- Implantable cardioverter-defibrillator (ICD), 9, 58, 59
- Inotropes, 57
- Integrins
 aging heart, 403–404
 apoptosis, 405–406
 ECM
 age-related changes, 381
 myocardial infarction, 383
 expression, 402–403
 hypertrophy, 406–407
 mechanotransduction, 405
 myocardial remodeling
 definition, 404
 role, 404–405
 signaling processes, 401
 structure and function
 ligand specificity, 401
 outside-in signaling, 402
 TGF- β , 402
 treating, aging heart, 407
- Ivabradine, 59
- IV inotropes, 59
- J**
- Juxtaglomerular (JG) cells, 168–169
- K**
- Kallikrein–Kinin system, 263–264
- L**
- Left ventricle (LV)
 diastolic dysfunction, 35, 37
 ejection fraction (EF), 35–38
 geometry, 38
 hypertrophy, 37–39, 96, 99
 remodeling, 6, 99
 stiffness, 40
- Leptin
 aging
 biomarkers, 311
 effect, 412
 HF biomarker
 clinical study, 413
 obesity vs. CVD, 412–413
 hyperleptinemia, 412
 production, 412
 signaling pathways, 412, 413
- Lipocalin-2, 420
- L-type Ca²⁺ channel, 325–327
- LV ejection fraction (LVEF), 7
- M**
- Macroscopic cardiac changes
 in aging, 99
 in HTN and DHF, 99–100
- Mammalian target of rapamycin (mTOR), 345
- Matricellular proteins, ECM
 age-related changes, 380–381
 myocardial infarction, 383

- Matrix metalloproteinase (MMPs), ECM
 age-related changes, 381
 myocardial infarction, 383
 Mechanotransduction, 405
 Metabolic syndrome, 24
 MI. *See* Myocardial infarction (MI)
 Microscopic cardiac changes, 96
 Mineralocorticoid receptor antagonist (MRA)
 adipocytes, 276
 aldosterone, 272
 β -adrenergic blocker, 272
 11 β HSD2, 275–276
 clinical trial, 272–273
 cortisol-induced activation, 274–275
 CYP11B1, 274
 diastolic dysfunction, 274
 EPHEsus study, 273
 gynecomastia, 273
 hyperkalemia, 277
 macrophages, 276
 mechanisms, 275
 MR activation, 274
 nuclear factor κ B (NF κ B), 276
 RALES study, 273
 renal function, 273
 serum potassium, 273
 transgenic overexpression, 276
 Mitochondria, 125
 cardiac, 439
 damaged, 442–444
 roles, 439, 445
 ROS and, 439–440
 Mitochondrial biogenesis, 442
 Mitochondrial DNA (mtDNA), 439
 Mitochondrial dysfunction, 439
 energy production, 439–440
 ROS generation, 439–440
 Mitochondrial fission/fusion system, 441–442
 Mitophagy, 442–445
 MPTP, 342–344
 Myocardial fibrosis, 96–98
 Myocardial infarction (MI)
 ECM
 collagens, 381–382
 glycoproteins, 382–383
 growth factors, 383–384
 hyaluronan, 383
 integrins, 383
 matricellular proteins, 383
 MMPs, 383
 temporal changes, 382
 elderly patients, 433–434
 heart failure, 23–24, 440–441
 Myocardial remodeling
 cardiac fibrosis, 362–363
 integrins
 β 1 integrin, 404–405
 definition, 404
 post-MI, 404
 Myocyte relaxation, 451
- N**
 Na⁺–Ca²⁺ exchanger (NCX), 329
 National Health Interview Survey, 162
 Necrosis
 aging effects, 339–340
 MPTP inhibitors, 344
 sirtuin inhibitors, 342–343
 Nesiritide, 56–57
 New York Heart Association (NYHA) classification
 system, 87
 Nitrates, 110
 Non-pharmacological therapies, 9–10
 N-terminal brain natriuretic peptide (N-BNP), 87
- O**
 Obesity
 exercise, 159–160
 heart failure, 24
 Omapatrilat (OMA), 9
 Omentin, 420
 Optimize therapy, SHF. *See also* Heart failure (HF),
 monitoring in clinics
 aging-related changes
 cardiovascular, 49–50
 cellular and subcellular, 50
 clinical implications, 50
 aldosterone antagonists, 53–54
 angiotensin converting enzyme inhibitors, 52–53
 angiotensin receptor blockers, 53
 anticoagulation, 57–58
 beta-blockers, 54–55
 caveats, 52
 clinical trials, 58–59
 comorbidities, 50–51
 CVD risk factors, 49
 demographics and epidemiology, 47–48
 device therapy, 58
 diastolic heart failure, 58
 diuretics, 55
 inotropes, 57
 nesiritide, 56–57
 organic nitrates, 56
 in organ systems, 51–52
 pathophysiological considerations, 49
 pharmacotherapy, 52
 sodium nitroprusside, 56
 vasodilators, 55
 Oral anticoagulants, 73–75
 Organic nitrates, 56
 Orthostatic changes, 51
 Oxidative modification, 449–454
 Oxidative stress
 aging biomarkers
 cyclophilin A, 308
 8-OH dG, 307
 role, 307
 calcium-handling defects, 396
 RAAS and, 461
 SMP30 and, 460

P

- Peripheral vasculature, 119–122
 - Pharmacological therapies
 - aging-related issues with, 8
 - caveats, 9
 - Pharmacotherapy, 52
 - Polypharmacy, 112–113
 - Polyunsaturated fatty acid (PUFA), 395
 - Post-MI remodeling, aging patients
 - gene expression therapy, 435
 - paracrine modulation, 434–435
 - reverse intracellular remodeling, 435
 - stem cell therapy, 434
 - Postural changes, 51
 - Prevention strategies
 - aging continuum, 21–22
 - beginning, 25–26
 - biological aging and the aging continuum, 25
 - cardiovascular risk, 21–22
 - biomarkers, 23
 - clustering, 22–23
 - chronological definition of elderly, biological aging, 25
 - education role, 26–27
 - and healthy aging, 26
 - telomeres, telomere length and telomerase activity, 18
 - Propafenone, 70
 - Proteoglycans, 380
 - Pulmonary arterial hypertension (PAH), 295–296
 - Pulmonary disease, 51
 - Pulmonary emboli, 297–298
 - Pulmonary hypertension (PHTN)
 - chronic obstructive lung disease, 298
 - definition, 291
 - diagnosis, 298–299
 - epidemiology, 294–295
 - pathogenesis, 294
 - pathophysiology, 291–292
 - prognosis and treatment, 299–300
 - pulmonary emboli, 297–298
 - right-sided heart failure, 293–294
 - right ventricular
 - dysfunction, 293
 - function, 292–293
 - left-sided heart failure, 296–297
 - pressure–volume loop, 295
 - primary arterial hypertension, 295–296
 - remodeling, 293
 - WHO classification, 292
 - Putative molecular mechanisms, 124–125
- R**
- RAAS. *See* Renin-angiotensin-aldosterone system (RAAS)
 - Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT), 141
 - Reactive interstitial fibrosis, 362
 - Reactive oxygen species (ROS)
 - cardiac aging, 450–451
 - cardiac fibrosis, 367–368
 - generation, 439–440
 - Regucalcin (RGN), 457, 458
 - Renal system, aging-related changes, 51
 - Renin-angiotensin-aldosterone system (RAAS)
 - aging-associated fibrosis, 367
 - effects, 170
 - heart failure
 - ACE escape, 171
 - ACE inhibitors, 171, 173
 - aldosterone, 171–172
 - aldosterone receptor antagonists, 174–175
 - angiotensin, 170–171
 - anti-renin therapy, 172
 - ARBs, 173–174
 - blood-borne humoral agents, 179
 - diastolic treatment, 178
 - diuretic-induced hyponatremia, 177–178
 - dyspnea, 167–168
 - endothelial dysfunction, 178–179
 - and MRAs, 175–176
 - nature of, 165–167
 - neurohumoral interactions in kidney, 168–170
 - sodium hemostasis, 176–177
 - symptomatology, 168
 - SMP30 and cardiovascular diseases, 461
 - Renin-angiotensin system (RAS)
 - ACE2/Ang-(1-7) pathway, 272
 - ACE inhibitors
 - adverse events, 268
 - cough and angioedema side effects, 267–268
 - non-ACE and non-renin pathway, 267
 - RCT, 267–268
 - AT₂ receptor stimulation, 268
 - VALIANT, 268
 - ACE pathway
 - canine model, 264
 - diabetes, 264–265
 - inhibitors, 264
 - mouse model, 264
 - AT₁ receptor blockade, 264
 - adverse remodeling, 260
 - Ang-(1–12), 266–267
 - AngII, AT₁/AT₂ pathway, 262
 - cardioprotective effects, 263–264
 - counter-regulatory/Ang-(1–7) arm, 265–266
 - dual-action molecules, 278
 - dysregulation pathway
 - components, 270
 - enalapril/losartan, 270
 - factors, 270–271
 - patient outcomes, 270
 - AT₂ receptor pathway, 271–272
 - upregulation, 271
 - endothelin system, 265
 - healthcare cost, 259–260
 - HF/PEF, 260–261
 - hypertension
 - aging process, 260, 268
 - aldosterone synthase inhibition, 277

- Renin-angiotensin system (RAS) (*cont.*)
 EUROPA trial, 269
 factors, 262, 269
 inhibition, 262, 269
 OPTIMAAL/VALIANT, 269–270
 PEACE trial, 269
 renin inhibition, 277–278
 risk factors, 261, 268–269
 MRA (*see* Mineralocorticoid receptor antagonist (MRA))
 oxidative stress, 261
 pharmacology, 262–263
 post-MI, 260–261
 risk factor, 260–261
 Reparative fibrosis, 362
 Reperfusion therapy, STEMI
 acute, 203
 mortality, 205
 SHOCK trial, 206
 Resistin
 as biomarker, 418
 heart failure
 association of, 245
 circulating concentration, 243–244
 Framingham offspring cohort, 246–247
 insulin resistance, 243
 multiple functions, 243
 Reynolds Risk Score (RRS), 22
 Right ventricle (RV)
 dysfunction, 293
 function, 292–293
 left-sided heart failure, 296–297
 pressure-volume loop, 295
 primary arterial hypertension, 295–296
 remodeling, 293
 Risk stratification
 cardiovascular computed tomography, 249
 CHD risk factors, 250
 Framingham/ATPIII, 251
 treatment goals, 250
 ROS. *See* Reactive oxygen species (ROS)
- S**
 SALT-1 and SALT-2 trials, 55
 Sarcoplasmic reticular calcium ATPase (SERCA)
 activation via S-glutathiolation in cardiac myocytes, 451
 oxidation contribute to cardiac aging, 453–454
 oxidative posttranslational modifications
 activation via reversible S-glutathiolation, 451
 inactivation via irreversible oxidation, 451–453
 redox regulation, 453
 Seattle Heart Failure Model (SHFM) score, 7
 Secreted protein acidic and rich in cysteine (SPARC)
 Frank Starling mechanisms, 190
 Nacl collagen, 190, 191
 regulatory mechanisms, 191
 Senescence, cardiac fibrosis, 361, 370–371
 Senescence marker protein 30 (SMP30)
 cardiovascular diseases and, 461–462
 identification, 457
 multiple biological function, 457–460
 oxidative stress and, 460
 Senility
 aging biomarkers, 305
 calcium-handling defects, 391
 SERCA. *See* Sarcoplasmic reticular calcium ATPase (SERCA)
 S-glutathiolation, 451–453
 Shelterin, 351
 SHF. *See* Systolic heart failure (SHF)
 Sirtuins
 apoptosis inhibition, 342
 autophagy, 343
 necrosis inhibition, 342–343
 SIRT1 and SIRT3, 342
 SMP30. *See* Senescence marker protein 30 (SMP30)
 Sodium hemostasis, heart failure, 176–177
 Sodium nitroprusside, 56
 SR Ca²⁺
 pump, 327–328
 release channel, 328–329
 Stem cell therapy, 434
 STEMI. *See* ST-segment-elevation myocardial infarction (STEMI)
 Stress protein, 19–20
 Stroke, 66–67
 risk with aging, 72
 ST-segment-elevation myocardial infarction (STEMI)
 aging and heart failure
 cardiovascular continuum, 201
 effects of, 204–205
 reasons for, 203
 remodeling post, 204–205
 risk factors, 205
 clinical trials
 ACE inhibitor, 204
 angiotensin receptor blockers, 207
 matrix metalloproteinases (MMPs), 204
 randomized clinical trials, 203
 definition, 202
 LV remodeling and dysfunction, 6, 7
 models of
 HF/low-EF, 203
 pump dysfunction, 202
 multiple hemodynamic mechanisms
 β-adrenergic stimulation, 209
 vasodilator drugs, 209
 Subcellular changes, aging-related, 50
 Sudden cardiac death, 244
 Systolic blood pressure (SBP), 312
 Systolic heart failure (SHF), 3, 47
 demographics and epidemiology, 47–48
 elderly patients with, 51
 management of, 52
 optimize therapy of (*see* Optimize therapy, SHF)
 therapy for, 59

T

Telomerase, 353

Telomeres

aging biomarkers, 310

ATL, 353

biological aging

dyskeratosis congenita, 353

length vs. life span, 354

senescence, 353

telomere attrition, 354

dysfunction, 124–125

and heart failure

carbon-dating techniques, 356

cardiac biopsies, 356

incidence and prevalence, 355

risk factor, 354–355

treatment, 357

length, activity, and implications, 18

length and healthy aging, 20

shortening

in cardiovascular disease, 18–19

and cellular senescence, 19

and heart failure, 19

structure and function

end replication problem, 351

telomere–shelterin complex, 352

TERRA, 353

telomere length maintenance, 353

Testosterone, 310

TGF- β , 368–369

Thiobarbituric acid reactive substances

(TBARS), 458

TIGAR. *See* Tp53-induced glycolysis and apoptosis regulator (TIGAR)

Titin, 184

Tolvaptan, 59

Tp53-induced glycolysis and apoptosis regulator (TIGAR), 443

Transplant, 59

Type 2 diabetes, heart failure, 24

V

Valsartan Heart Failure (Val-HeFT), 141

Vasodilators, 55, 59

reperfusion, 200, 203, 205, 206

therapy

ACE inhibitors, 208

factors affecting response, 210

RAAS inhibitors, 210

Vaspin, 420

Ventricular assist device (VAD), 59

Ventricular remodeling, 432–433

Visfatin/NAMPT, 419–420

W

White adipose tissue (WAT), 411. *See also* Adipokines